CAJ | 학술논문

目的探讨伊洛马司他联合化疗药物卡培他滨对人喉癌hep-2细胞生长的影响。方法伊洛马司他、卡培他滨两药单独和联合处理hep-2细胞，未处理组为对照组，采用甲基偶氮唑盐（MTT）法分析hep-2细胞的增殖活性，并采用金氏Q值判断联合用药的性质；逆转录-聚合酶链反应（RT-PCR）检测hep-2细胞中基质金属蛋白酶-9（MMP-9）mRNA的表达水平；流式细胞术检测hep-2细胞的凋亡率。结果伊洛马司他与卡培他滨对hep-2细胞均有抑制作用，联合用药细胞抑制率明显增高（P＜0．05），两药联合浓度为（8＋100）μg/mL时为协同作用，（40＋400）μg/mL时为相加作用；RT-PCR示伊洛马司他组与联合用药组的MMP-9mRNA的表达水平均低于对照组（P＜0．05），联合用药组MMP-9mRNA的表达水平低于伊洛马司他组（P＜0．05）；流式细胞术示伊洛马司他组及卡培他滨组的凋亡率高于对照组（P＜0．05），联合用药组的凋亡率高于其他各组（P＜0．05）。结论
목적탐토이락마사타연합화료약물잡배타빈대인후암hep-2세포생장적영향。방법이락마사타、잡배타빈량약단독화연합처리hep-2세포，미처리조위대조조，채용갑기우담서염（MTT）법분석hep-2세포적증식활성，병채용금씨Q치판단연합용약적성질；역전록-취합매련반응（RT-PCR）검측hep-2세포중기질금속단백매-9（MMP-9）mRNA적표체수평；류식세포술검측hep-2세포적조망솔。결과이락마사타여잡배타빈대hep-2세포균유억제작용，연합용약세포억제솔명현증고（P＜0．05），량약연합농도위（8＋100）μg/mL시위협동작용，（40＋400）μg/mL시위상가작용；RT-PCR시이락마사타조여연합용약조적MMP-9mRNA적표체수평균저우대조조（P＜0．05），연합용약조MMP-9mRNA적표체수평저우이락마사타조（P＜0．05）；류식세포술시이락마사타조급잡배타빈조적조망솔고우대조조（P＜0．05），연합용약조적조망솔고우기타각조（P＜0．05）。결론
Objective To explore the effect of ilomastat combined with chemotherapeutic drug capecitabine on human laryngeal cancer hep-2 cell .Methods hep-2 cells were treated by ilomastat and capecitabine alone and their combination .The untreated group was taken as the control group .The proliferation activity of the hep-2 cells was analyzed by MTT assay ,and the Jin′s Q was adopt-ed to assess the characters of combination medication of ilomastat and capecitabine ;the expression level of MMP-9mRNA in hep-2 cell was detected by RT-PCR;the apoptosis rate of hep-2 cell was detected by the flow cytometry .Results Both ilomastat and capecitabine had the inhibiting effect on the proliferation of hep-2 cell ,and the combination of ilomastat and capecitabine increased the cell inhibitory rate(P<0 .05) ,the interaction between ilomastat and capecitabine was the synergistic effect when the combined concentration was (8+100)μg/mL ,while the interaction between ilomastat and capecitabine was the additive action when the com-bined concentration was (40+ 400)μg/mL ;RT-PCR analysis showed that compared with control group ,the expression level of MMP-9mRNA in the single ilomastat group and the combination group were both decreased (P< 0 .05) ,and the expression of MMP-9mRNA in the combination group was lower than that in the single ilomastat group (P<0 .05);the flow cytometry indicated that the apoptosis rate of hep-2 cell in the single ilomastat group and the single capecitabine group were both higher than that in the control group(P<0 .05) ,and the apoptosis rate in the combination group was higher than that in the other groups (P<0 .05) .Con-clusion Ilomastat combined with capecitabine can obviously enhance the inhibition and apoptosis-induced ability of single drug on laryngeal cancer hep-2 cell ,the action mechanism of ilomastst is down-regulation of the expression level of the MMP-9 mRNA .